Anti-CD20 chimeric monoclonal antibody (CD20-ab) has been demonstrated to be effective for the treatment of low-grade B cell lymphoma. Although complement-mediated cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) are thought to have an inhibitory effect on tumor cells in vivo, the exact mechanism of cell death remains to be clarified.
Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody
TO THE EDITOR Anti-CD20 chimeric monoclonal antibody (CD20-ab) has been demonstrated to be effective for the treatment of low-grade B cell lymphoma. Although complement-mediated cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) are thought to have an inhibitory effect on tumor cells in vivo, the exact mechanism of cell death remains to be clarified.
Various investigators with different experimental models have examined the tumoricidal mechanism of monoclonal antibodies. In a mouse xenograft model system using human B cell lymphoma, it was shown that ADCC by CD20-ab was the major tumoricidal mechanism in vivo. 1 In cell culture system, Golay et al 2 examined in vitro cytotoxic mechanisms and concluded that CDC and ADCC were the major tumoricidal mechanisms in vivo. They demonstrated that CD20ab blocks the proliferation of normal B cells induced by SAC, but not of those induced by anti-and anti-CD40. They also found no direct growth suppression by CD20-ab for B-cell line SU-DHL-4. However, their findings regarding antibody-mediated growth suppression in vitro contradict our previous observation that CD20-ab demonstrated direct growth suppression for at least four independent B cell tumors including SU-DHL-4 although the level of suppression varied among the cell lines. 3 Our data do not necessarily negate their conclusion that CDC and ADCC constitute the major pathways of action on B cell lymphoma, but we do not agree that direct growth suppression by CD20-ab does not occur. Our tissue culture system utilizes fetal bovine serum that was heat-inactivated at 56°C for 30 min and kept at 4°C for more than 2 weeks for ageing, therefore, CDC should not take place in our culture system. SU-DHL-4, in particular, shows growth suppression and accumulation of dead cells (Figure 1 ) as demonstrated at two different concentrations in experiments that were reproducible as described in a previous paper of ours.
The action mechanism of an antibody in vivo may not be regarded as an important issue as long as the antibody is a single therapeutic agent, but it becomes important when it is used in conjunction with other therapies, such as chemotherapy. If direct suppression is caused partly by apoptosis as shown in our previous experiment, enhancement of such a pathway needs to be considered. If ADCC is the major pathway, the chemotherapeutic adverse effect on effector cells should be thoroughly examined. The results of such an investigation can be expected to provide a strategic rationale for combination chemotherapy with CD20-ab. In this context, several protocol studies being examined 4 that varied the time of antibody inoculation, may explore important insights into the major in vivo tumoricidal mechanism.
T Oyama Growth curves of SU-DHL-4 in the absence (a) or presence of 10 g/ml (b) or 100 g/ml (c) of chimeric anti-CD20 antibody. Five ml of 5 × 10 4 /ml SU-DHL-4 was cultured in a six-well cluster dish (Costar, Cambridge, MA, USA) and the number of cells was counted every 2 days by using the trypan blue dye exclusion test. Arrows show the time point when the cultured cells were split to one third. Results of a representative experiment are shown. Broken lines, the number of dead cells; solid lines, the number of viable cells.
